AstraZeneca's MedImmune Division to Acquire Amplimmune for up to $500M

AstraZeneca (NYSE: AZN ) today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology. The acquisition will bolster MedImmune's oncology pipeline by obtaining multiple early-stage assets